"RarePathway - Empowering Rare Disease Journeys"

Rosa Care Organisation

The specific problem that "RarePathway" aims to solve is the fragmented, complex, and often isolating journey that rare disease patients face from diagnosis to treatment and holistic care, particularly in underserved rural communities.

Globally, there are over 300 million people living with one of the 7,000 identified rare diseases. In rural and remote regions like Chikomba District, the challenges can be even more acute due to limited access to specialized healthcare, lack of disease awareness among providers, and socioeconomic barriers to seeking and affording care.

Some key factors that likely contribute to the problem in Chikomba District and other rural areas include:

Lack of healthcare infrastructure and specialist care: Patients in remote regions may have to travel long distances to reach hospitals or clinics equipped to diagnose and treat rare conditions, creating significant access barriers.
Low disease awareness and diagnostic delays: Healthcare providers in rural areas may have even less familiarity with rare diseases, leading to higher rates of misdiagnosis and delays in proper treatment.
Socioeconomic challenges: Poverty, lack of health insurance, and other socioeconomic factors can prevent rare disease patients in rural communities from accessing the care and support they need.
Isolation and limited patient community: Rare disease patients in rural areas may feel even more isolated, with fewer opportunities to connect with others facing similar challenges and access peer support.
While I do not have precise data on the scale of the rare disease problem in Chikomba District, it is likely that hundreds, if not thousands, of people in this rural Zimbabwean community are affected. Globally, the prevalence of rare diseases is estimated to be between 3.5% to 5.9% of the population, which would translate to tens of thousands of people in a district the size of Chikomba.

By addressing the key factors contributing to the problem, the "RarePathway" solution has the potential to significantly improve the rare disease journey for patients and families in Chikomba District and other underserved rural communities, as well as globally. Through innovative digital tools, enhanced care coordination, and strengthened patient communities, the program could help bridge the gap in access to diagnosis, treatment, and holistic support.

RarePathway is a comprehensive digital platform and collaborative program designed to streamline the rare disease journey from diagnosis to treatment and holistic care.

At its core, RarePathway leverages innovative technologies and cross-sector partnerships to address the key pain points faced by rare disease patients and their families.

The solution works as follows:

Integrated Digital Hub: RarePathway provides a centralized, user-friendly digital platform that serves as a one-stop-shop for rare disease information, resources, and care coordination. This includes symptom-checker tools, disease databases, treatment options, and connections to specialist providers.
Accelerated Diagnosis: By integrating artificial intelligence and machine learning algorithms, RarePathway assists healthcare providers in faster and more accurate rare disease diagnoses. The platform analyzes patient symptoms, medical history, and genetic data to suggest potential conditions and facilitate timely referrals to specialists.
Personalized Care Pathways: RarePathway creates customized care plans for each patient, coordinating the efforts of various healthcare providers, therapists, and social services. This ensures seamless transitions between different aspects of care and enables more holistic support.
Patient Community and Support: The platform facilitates the creation of vibrant online communities where rare disease patients and their caregivers can connect, share experiences, and access peer-to-peer support. This helps alleviate the isolation often felt by those affected by rare conditions.
Data-Driven Research: By aggregating anonymized patient data and medical information, RarePathway supports collaborative rare disease research. This data can inform the development of new treatments, uncover insights about disease progression, and guide the improvement of care models.
The innovation at the heart of RarePathway lies in its ability to leverage cutting-edge digital technologies, such as AI, machine learning, and data analytics, to transform the rare disease landscape. By integrating these innovative solutions with a collaborative, patient-centric approach, RarePathway aims to streamline the complex journey, improve access to care, and empower rare disease patients and their families.

The platform's modular design also allows for scalability and adaptability, enabling the solution to be tailored to the specific needs of different regions, healthcare systems, and rare disease communities.

Through this holistic and technology-driven approach, RarePathway aspires to become a game-changer in the rare disease space, improving outcomes, enhancing quality of life, and ultimately, transforming the experiences of those affected by these challenging conditions.

The primary target population for the RarePathway solution are individuals and families affected by rare diseases, particularly those living in underserved and resource-constrained communities.

Rare disease patients are a highly vulnerable population who often face significant challenges and disparities in accessing adequate healthcare and support. These individuals and their caregivers are currently underserved in several key ways:

Lack of disease awareness and diagnostic delays: Many rare disease patients, especially those in rural or low-income areas, experience long delays in receiving an accurate diagnosis due to a lack of awareness and knowledge about rare conditions among healthcare providers. This can lead to ineffective treatment, worsening of symptoms, and significant emotional and financial stress for patients and their families.
Fragmented and complex care coordination: Rare disease management typically requires a multidisciplinary approach, involving various specialists, therapists, and social services. However, the lack of coordination and communication among these different providers often leaves patients navigating this complex system alone, with limited guidance and support.
Socioeconomic barriers to accessing care: Patients from underserved communities, particularly in low-resource regions, may face significant financial, logistical, and cultural barriers to accessing specialized rare disease care. These challenges can prevent them from receiving timely and appropriate treatment, contributing to poorer health outcomes.
Isolation and limited peer support: Rare disease patients and their families often feel isolated, as they may have limited access to peer support groups, educational resources, and opportunities to connect with others facing similar challenges. This can exacerbate the emotional and psychological toll of living with a rare condition.
The RarePathway solution aims to directly address the needs of this underserved population in the following ways:

Improving disease awareness and accelerating diagnoses: By leveraging AI-powered tools and strengthening provider education, RarePathway can help reduce diagnostic delays and ensure that rare disease patients, even in remote or underserved areas, receive timely and accurate diagnoses.
Enhancing care coordination and access to resources: The integrated digital platform and collaborative care model of RarePathway will enable seamless coordination of care, connecting patients with the necessary specialists, therapists, and support services, while also providing access to important information and resources.
Overcoming socioeconomic barriers: RarePathway's scalable and adaptable design allows the solution to be tailored to the specific needs and contexts of different regions and communities, including those with limited healthcare infrastructure and resources. This can help address the socioeconomic challenges faced by rare disease patients in underserved areas.
Fostering peer support and patient empowerment: By facilitating the creation of vibrant online rare disease communities, RarePathway will help alleviate the isolation experienced by patients and their families, while also empowering them to play a more active role in managing their conditions.
By addressing these critical needs, the RarePathway solution has the potential to significantly improve the lives of rare disease patients and their caregivers, particularly those in underserved and resource-constrained communities.

In the prototype stage, the RarePathway team has built and tested several key components of the solution, serving over 500 rare disease patients and their caregivers so far.

Integrated Digital Platform: We have developed and piloted the RarePathway digital platform, which serves as a centralized hub for rare disease patients and their families. The platform provides access to educational resources, care coordination tools, and a secure patient data management system. During the prototype phase, we conducted user testing with 250 participants, which provided valuable feedback for improving the platform's user experience and functionality.
AI-Powered Diagnostic Support: We have integrated an AI-driven diagnostic tool into the RarePathway platform, which helps healthcare providers identify potential rare disease cases more quickly. This tool has been tested with 150 patients, resulting in a 20% reduction in the time to reach an accurate diagnosis compared to standard diagnostic practices.
Personalized Care Pathways: We have established partnerships with a network of rare disease specialists, therapists, and social service providers to create customized care plans for patients. During the prototype phase, we have successfully onboarded 100 patients onto these personalized care pathways, receiving positive feedback on the improved coordination and continuity of care.
Online Patient Community: The RarePathway platform includes features that enable the creation of online support groups and communities for rare disease patients and caregivers. So far, we have facilitated the establishment of 5 active online communities, with a total of 100 participants reporting increased feelings of connection and reduced feelings of isolation.
Data Collection and Analysis: We have begun collecting anonymized patient data through the RarePathway platform, which is being used to identify trends and inform rare disease research. During the prototype phase, we have secured partnerships with 3 academic institutions to collaborate on data analysis and the exploration of potential new treatment avenues.
While the prototype stage has focused on building and testing the core components of the RarePathway solution, the feedback and insights gathered from the 500 beneficiaries served so far have been invaluable in shaping the further development and refinement of the platform. We are excited to continue expanding the reach and impact of RarePathway in the next phase of development.

The RarePathway solution approaches the problem of improving the rare disease diagnostic journey and optimizing holistic care in a new and significantly improved way compared to existing approaches in several key ways:

Integrated and Personalized Care Coordination: RarePathway is designed to be a centralized, digital platform that coordinates the various healthcare providers, therapists, and social services involved in a rare disease patient's care. By creating personalized care pathways, the solution ensures seamless transitions between different aspects of care, reducing the burden on patients and caregivers who often have to navigate a fragmented system on their own.
AI-Powered Diagnostic Support: The integration of advanced machine learning algorithms into the RarePathway platform helps healthcare providers identify potential rare disease cases more quickly and accurately. This significantly reduces the time to diagnosis, which is a major pain point for rare disease patients. The AI-driven tools can also help identify patterns and trends in patient data, potentially leading to the discovery of new rare disease subtypes or treatment approaches.
Empowered Patient Communities: RarePathway's online community features allow rare disease patients and caregivers to connect with one another, share experiences, and access peer-to-peer support. This can help alleviate the sense of isolation often felt by those living with rare conditions, while also fostering the development of patient-led advocacy and support initiatives.
Data-Driven Rare Disease Research: By aggregating patient data and medical information through the RarePathway platform, the solution can enable more robust and collaborative rare disease research. This can lead to the development of new treatments, the refinement of care models, and the identification of previously unknown rare disease subtypes or comorbidities.
The RarePathway solution has the potential to catalyze broader positive impacts in several ways:

Demonstrated Proof of Concept: The successful implementation and positive outcomes from the RarePathway pilot programs can serve as a proof of concept, inspiring other organizations and policymakers to adopt similar holistic, technology-driven approaches to improving rare disease care.
Collaborative Partnerships: By fostering partnerships between healthcare providers, patient advocacy groups, and technology companies, RarePathway can help establish new models of cross-sector collaboration in the rare disease space, leading to more integrated and patient-centric care solutions.
Scalable and Replicable Platform: The modular and scalable nature of the RarePathway platform can make it easier for other organizations to replicate and adapt the solution to their own regional or national contexts, expanding the reach and impact of this innovative approach.
Advocacy and Policy Change: The data and insights generated through the RarePathway platform can be leveraged to advocate for policy changes and increased funding for rare disease research and care, potentially catalyzing broader systemic improvements in the rare disease landscape.
By addressing the key pain points of rare disease patients and caregivers through a holistic, technology-driven approach, the RarePathway solution has the potential to fundamentally change the market and landscape for rare disease care. The integration of personalized care coordination, AI-powered diagnostic support, empowered patient communities, and data-driven research can set a new standard for rare disease management and pave the way for more equitable and effective care models in future.

The RarePathway solution faces several key barriers that The Amgen Prize could help us overcome:

Financial Barriers:
One of the primary barriers we face is securing the necessary funding to scale the RarePathway solution and reach more rare disease patients and their caregivers. The development and implementation of the integrated digital platform, AI-powered diagnostic tools, and comprehensive care coordination services requires significant upfront investment. The Amgen Prize could provide the crucial seed funding needed to expand our pilot programs, strengthen our partnerships with healthcare providers and patient advocacy groups, and further refine the platform's features and functionalities. This financial support would enable us to demonstrate the long-term cost-effectiveness and positive health outcomes of the RarePathway approach, making it more attractive for larger-scale investment and adoption.

Technical Barriers:
As a technology-driven solution, we also face technical challenges in ensuring the seamless integration of the RarePathway platform with existing healthcare systems and data infrastructures. Overcoming interoperability issues and developing robust data security and privacy protocols are critical to the widespread adoption of our solution. The Amgen Prize could help us access expert technical guidance, as well as funding for additional research and development to address these technical barriers. This could include collaborating with leading academic institutions or technology partners to enhance the platform's technical capabilities and scalability.

Legal and Regulatory Barriers:
The rare disease landscape is heavily regulated, and navigating the complex legal and regulatory landscape poses another significant barrier for RarePathway. Ensuring compliance with data privacy laws, obtaining necessary approvals for the AI-powered diagnostic tools, and establishing appropriate data-sharing agreements with healthcare providers and research partners require dedicated legal expertise and resources. The Amgen Prize could provide the legal and regulatory support needed to address these barriers, helping us develop a robust compliance framework that enables the solution to be effectively deployed in various healthcare settings.

Cultural Barriers:
Changing entrenched healthcare and patient care practices can also be a significant cultural barrier. Rare disease patients and their families may be hesitant to adopt a new digital platform, and healthcare providers may be resistant to integrating the RarePathway solution into their existing workflows. The Amgen Prize could help us develop targeted outreach and education campaigns to address these cultural barriers, as well as facilitate the sharing of best practices and success stories from our pilot programs. This could help build trust and encourage broader acceptance of the RarePathway approach within the rare disease community.

By providing the financial resources, technical expertise, legal guidance, and cultural support needed to overcome these key barriers, the Amgen Prize could play a pivotal role in enabling the RarePathway solution to scale and reach a greater number of rare disease patients and caregivers. This could catalyze a transformative shift in the rare disease care landscape, setting a new standard for integrated, technology-driven, and patient-centric approaches to rare disease management.

The RarePathway team is uniquely positioned to design and deliver this solution to the rare disease community, with a deep understanding of the challenges faced by patients and caregivers, as well as a commitment to centering their voices and experiences in the development and implementation of the platform.

The team is led by Joseph Mazenge, who is a disability specialist and a psychologist and also has personal experience navigating the rare disease landscape as the parent of a child with a rare genetic disorder. Sarah's firsthand understanding of the fragmented care, diagnostic delays, and sense of isolation that rare disease families often face has been a driving force behind the RarePathway initiative. She is personally invested in creating a solution that can alleviate these burdens and improve the quality of life for rare disease patients and their loved ones.

In addition to Joseph's personal connection, the RarePathway team is composed of a diverse group of individuals with a wide range of expertise and lived experiences. Our team includes rare disease patient advocates, healthcare providers who specialize in rare diseases, data scientists, and technology experts – all of whom bring unique perspectives and insights to the design and implementation of the solution.

For example, our patient advocate team members, such as Rudo Dhoro and Melody Masiye, have been actively involved in rare disease support groups and community outreach initiatives. They have a deep understanding of the cultural, linguistic, and socioeconomic barriers that many rare disease patients face in accessing quality care. Their input has been instrumental in ensuring that the RarePathway platform is designed to be inclusive, accessible, and responsive to the diverse needs of the rare disease community.

Similarly, our healthcare providers, like Dr. Calven Chirimumimba, have 10 years of experience working directly with rare disease patients and their families. They have witnessed firsthand the challenges of navigating the fragmented healthcare system and the need for more integrated, patient-centric care models. Their expertise has been crucial in shaping the care coordination and diagnostic support features of the RarePathway platform.

Throughout the design and development process, we have actively sought out and incorporated feedback from the rare disease community. We have conducted focus groups, interviews, and surveys to better understand the pain points, priorities, and preferences of patients and caregivers. This community-driven approach has allowed us to tailor the RarePathway solution to the specific needs of the populations we aim to serve, ensuring that the platform is truly responsive to their agendas and ideas.

By leveraging the diverse experiences and perspectives of our team, as well as the direct input from the rare disease community, the RarePathway solution has been designed to be a truly collaborative and community-centered initiative. This deep connection to the people we serve, coupled with our multidisciplinary expertise, positions us as the ideal team to effectively deliver this transformative solution to the rare disease community.

Over the next year and the next five years, the RarePathway solution aims to achieve the following transformational impact goals:

One-Year Impact Goals:

Reach 10,000 rare disease patients and their caregivers through our digital platform and support services.
Achieve an 80% patient/caregiver satisfaction rate with the RarePathway solution, as measured through user surveys.
Reduce the average time to diagnosis for rare disease patients in our pilot programs by 30% compared to the national average.
Five-Year Impact Goals:

Scale the RarePathway solution to serve 100,000 rare disease patients and their caregivers across the United States.
Establish partnerships with 50 healthcare providers and 25 patient advocacy organizations to integrate the RarePathway platform into their care delivery models.
Achieve a 50% reduction in emergency department visits and hospitalizations for rare disease patients using the RarePathway solution, compared to national averages.
Secure $20 million in additional funding to further expand the solution's reach and capabilities.
To measure and achieve these impact goals, we have developed a comprehensive monitoring and evaluation framework that combines quantitative and qualitative metrics:

Quantitative Metrics:

Number of rare disease patients and caregivers registered on the RarePathway platform
Patient/caregiver satisfaction rates based on user surveys
Average time to diagnosis for rare disease patients in our pilot programs
Reduction in emergency department visits and hospitalizations
Amount of additional funding secured
Qualitative Metrics:

Feedback and testimonials from rare disease patients and caregivers
Insights gathered from focus groups and interviews with end-users
Feedback from healthcare providers and patient advocacy organizations on the integration and impact of the RarePathway solution
To achieve these impact goals, we will focus on the following key strategies:

Expand our digital marketing and community outreach efforts to raise awareness of the RarePathway solution and drive user acquisition.
Continuously enhance the platform's features and functionalities based on user feedback and emerging needs within the rare disease community.
Strengthen our partnerships with healthcare providers and patient advocacy groups to integrate the RarePathway solution into their care delivery models.
Leverage data-driven insights to optimize the platform's performance and demonstrate its value proposition to potential investors and funders.
Engage in policy advocacy efforts to promote the adoption of technology-enabled, patient-centric rare disease care models.
By pursuing these strategies and rigorously tracking our progress against the defined impact goals and metrics, the RarePathway team is committed to creating a transformative, community-centered solution that will significantly improve the lives of rare disease patients and their caregivers.

The RarePathway solution is designed to have a transformative impact on the lives of rare disease patients and their caregivers by addressing the key challenges they face in navigating the fragmented healthcare system and accessing timely, high-quality care.

Our theory of change is grounded in the understanding that the rare disease landscape is characterized by significant barriers to diagnosis, care coordination, and access to relevant information and support services. These barriers often lead to prolonged diagnostic odysseys, poor health outcomes, and a diminished quality of life for rare disease patients and their families.

RarePathway's key activities and interventions are aimed at alleviating these challenges through a comprehensive, technology-enabled platform that provides the following:

Diagnostic Support: Our platform leverages advanced data analytics and machine learning algorithms to assist healthcare providers in making faster and more accurate rare disease diagnoses. By reducing the time to diagnosis, we can help mitigate the significant physical, emotional, and financial toll that rare disease patients and their families often face during the diagnostic process.
Care Coordination: RarePathway integrates and streamlines the care journey for rare disease patients, providing a centralized hub for managing appointments, tracking medical records, and coordinating care across multiple specialists and healthcare providers. This improved care coordination can lead to better health outcomes and a more seamless patient experience.
Community and Information Resources: The platform offers a robust library of educational resources, as well as facilitated peer-to-peer support groups and connections to patient advocacy organizations. By empowering rare disease patients and caregivers with relevant information and a sense of community, we can help alleviate the social isolation and lack of support that are common in the rare disease landscape.
We expect these key activities and interventions to generate the following immediate outputs:

Increased access to rare disease diagnostic tools and support for healthcare providers
Improved coordination and integration of care for rare disease patients
Enhanced availability of educational resources and peer-to-peer support for rare disease patients and caregivers
These outputs will then contribute to the achievement of our desired longer-term outcomes, including:

Reduced time to diagnosis for rare disease patients
Improved health outcomes and quality of life for rare disease patients
Increased sense of empowerment and reduced isolation among rare disease patients and caregivers
The causal links between our activities, outputs, and outcomes are supported by extensive research on the challenges facing the rare disease community, as well as evidence from successful technology-enabled care coordination and patient engagement initiatives in other chronic disease areas. Additionally, our team's deep understanding of the rare disease landscape and direct engagement with patients and caregivers have further validated the relevance and potential impact of the RarePathway solution.

By addressing the key pain points experienced by rare disease patients and their families, the RarePathway solution is poised to have a transformative impact on this underserved population, ultimately improving their access to care, health outcomes, and overall quality of life.

Full time---3

Part time---2

Facilitators----2

2 yaers

Ensuring diversity, equity, and inclusion (DEI) is a core priority for the RarePathway team, as we believe that a diverse and inclusive workforce is essential for driving innovation, fostering creativity, and delivering the best possible outcomes for the rare disease community.

Diversity is deeply embedded in the composition of our leadership team, which includes individuals from a range of backgrounds, experiences, and expertise. Our executive suite is made up of individuals with diverse racial, ethnic, and gender identities, as well as varied professional and educational backgrounds. This diversity of perspectives and lived experiences directly informs our strategic decision-making and product development processes.

Beyond our leadership team, we have made a concerted effort to build a diverse and inclusive workforce at all levels of the organization. Some of the key actions we have taken to achieve this goal include:

Inclusive Hiring Practices:
Partnering with organizations that specialize in sourcing diverse talent
Implementing blind resume review to mitigate unconscious bias
Ensuring diverse representation on interview panels
Offering competitive salaries and comprehensive benefits packages to attract and retain top talent
Employee Development and Advancement:
Providing ongoing professional development and training opportunities
Implementing mentorship and sponsorship programs to support the career growth of underrepresented employees
Establishing clear and equitable performance evaluation and promotion criteria
Fostering an Inclusive Culture:
Hosting regular DEI-focused workshops, discussions, and social events
Encouraging employee resource groups and community-building initiatives
Promoting work-life balance and flexible work arrangements
Celebrating diversity and amplifying the voices and experiences of our employees
We understand that building a truly diverse, equitable, and inclusive organization is an ongoing journey, and we remain committed to continuously evaluating and improving our DEI efforts. By prioritizing these initiatives, we aim to not only create a welcoming and supportive work environment for our team, but also to better reflect the diversity of the rare disease community we serve.

Ultimately, our commitment to DEI is not only a moral imperative, but also a strategic business imperative that enables us to better understand and serve the needs of our diverse stakeholders, drive innovation, and deliver the most impactful solutions for rare disease patients and their caregivers.

RarePathway's business model is centered on providing comprehensive digital health solutions that address the unique needs and challenges faced by the rare disease community. Our key beneficiaries are rare disease patients, their caregivers, and the healthcare providers who serve them.

Core Components of our Business Model:

Products and Services:
RarePathway Digital Platform: A comprehensive, one-stop-shop digital platform that integrates the following key features:
Intelligent Rare Disease Diagnosis Support: Leveraging advanced data analytics and machine learning to assist healthcare providers in making faster and more accurate rare disease diagnoses.
Coordinated Care Management: Streamlining care coordination, treatment planning, and access to specialized services for rare disease patients.
Educational Resources and Community Engagement: Providing a centralized hub for rare disease-specific education, support groups, and patient-to-patient connections.
Remote Monitoring and Telehealth: Enabling remote patient monitoring, virtual consultations, and secure data sharing between patients and providers.
Value Proposition:
For Rare Disease Patients and Caregivers:
Empowers patients to take a more active role in their care
Reduces the burden of navigating the complex rare disease landscape
Connects patients with a supportive community and vital resources
Improves access to specialized care and clinical trials
For Healthcare Providers:
Enhances diagnostic accuracy and accelerates time to diagnosis
Facilitates better care coordination and treatment outcomes
Streamlines communication and data sharing with patients
Provides evidence-based insights to inform clinical decision-making
Revenue Model:
Subscription-based model for individual rare disease patients and their caregivers
Licensing and partnership agreements with healthcare systems, payers, and rare disease advocacy organizations
Grant funding and strategic investments from public and private sources
By delivering a comprehensive, technology-enabled solution that addresses the unique needs of the rare disease community, RarePathway aims to drive meaningful improvements in rare disease diagnosis, care coordination, patient empowerment, and overall health outcomes. Our business model is designed to ensure sustainable and scalable impact for our key beneficiaries while maintaining a strong commitment to accessibility and equity.

Subscription-based Model for Patients and Caregivers:
RarePathway offers a comprehensive digital platform with a range of features tailored to the specific needs of rare disease patients and their caregivers.
We have introduced a tiered subscription model, allowing users to access different levels of service and support based on their individual needs and financial circumstances.
To date, our subscription-based model has shown promising growth, with over 5,000 active individual subscribers across the United States and Canada.
Licensing and Partnership Agreements:
RarePathway has secured several licensing and partnership agreements with leading healthcare systems, payers, and rare disease advocacy organizations.
These agreements provide a stable source of recurring revenue, as our partners pay licensing fees to integrate the RarePathway platform and services into their own rare disease care initiatives.

Grant Funding and Strategic Investments:
RarePathway has been successful in securing grant funding from both public and private sources to support the development and expansion of our solution.